CARRICK THERAPEUTICS LIMITED

Carrick Therapeutics Limited is a clinical‑stage biopharmaceutical company dedicated to developing next‑generation oncology medicines. Leveraging in‑house and in‑licensed assets, the firm targets the most aggressive and treatment‑resistant forms of cancer, with a focus on advanced breast, prostate and ovarian tumours and potential applications in pancreatic cancer and Ewing’s sarcoma.

Its pipeline centres on two novel inhibitors: Samuraciclib, a CDK7 inhibitor, and CT7439, a first‑in‑class CDK12/13 inhibitor. Both agents are being evaluated in combination with existing oncology drugs, aiming to improve outcomes for patients with hormone‑receptor‑positive, HER2‑negative advanced breast cancer and other hard‑to‑treat malignancies.

Carrick works closely with pharmaceutical partners, a network of clinicians and leading research institutions to accelerate clinical development. The company’s mission is to translate cutting‑edge science into therapies that address unmet patient needs and ultimately enhance survival and quality of life for cancer patients.